Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 21, 2018
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - October 21, 2018

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/20/18 - 51 Drug Dealers Arrested in Allegheny County Roundup
Pennsylvania Attorney General Josh Shapiro issued the following news release:. Attorney General Josh Shapiro today announced criminal charges against 51 people for selling heroin, fentanyl, illegal prescription opioids, cocaine, and other drugs in Allegheny County. Many of the arrests in today's roundup were for people considered mid-level drug dea
10/20/18 - AHPA Corrects JAMA Article That Misidentifies Illegal Drugs as Dietary Supplements
The American Herbal Products Association issued the following news release:. In a letter to the editor submitted to JAMA Open Network, American Herbal Products Association President Michael McGuffin stressed that the herbal products industry shares concerns about unapproved drugs masquerading as dietary supplements, as outlined in a recent article,
10/20/18 - Amendment 3 will fund research, provide construction jobs [Gulf Marketing Review (Middle East)]
The pharmaceutical companies contribute large amounts of money to members of Congress and state legislatures to lobby them. Prescription drugs are so exorbitant that alternatives should be a right of the people. Amendment 3 would develop three research facilities to find cures for cancer and chronic diseases and provide $66 million of construction
10/20/18 - An FDA Approved Generic Form of Ampyra Is Launched in the U.S.
The National Multiple Sclerosis Society issued the following news:. A generic equivalent of Ampyra, a treatment that is approved to improve walking in adults with MS, has been approved by the U.S. Food and Drug Administration and launched by Mylan NV. Dalfampridine extended-release tables 10 mg are currently available.
10/20/18 - Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX2-73 in Patients with Rett Syndrome [Syrian Arab News Agency]
-Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimers disease, Rett syndrome and other central nervous system diseases, today announced that the Company has received confirmation from the U.S. Food...
10/20/18 - Attorney General Frosh appeals to U.S. Supreme Court to uphold Maryland's law curbing drug price-gouging [The Baltimore Sun]
Oct. 19 Maryland Attorney General Brian Frosh on Friday appealed to the U.S. Supreme Court an earlier decision by a federal court that struck down a Maryland law to curb unreasonable price increases for generic drugs. In response to an industry challenge, the 4th U.S. Circuit Court of Appeals decided in April that the first-of-its-kind legislatio
10/20/18 - BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, today disclosed additional data from the in-depth analyses of biopsies of the dual combination arm of the Phase 2 a COMBAT/KEYNOTE-202 study, evaluating patients with metastatic pancreatic adenocarcinoma treated with BL-8040 in combination with KEYTRUDA..
10/20/18 - Biopharmaceutical Contract Manufacturing Market Growth by 2027 : Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH: Biopharmaceutical Contract Manufacturing Market Segmentation By Platform Mammalian, Microbial; By Applicatio
Valley Cottage, NY 10/19/2018 A new study by FMI titled' Biopharmaceutical Contract Manufacturing Market: Global Industry Analysis 2012 2016 and Opportunity Assessment 2017 2027', has listed out the key points being considered by Biopharmaceutical contract manufacturing companies to emerge and stay sustainably profitable in the long run
10/20/18 - Biotech IPOs For The Week Ahead
Alzheon is a U.S. clinical-stage biopharmaceutical company developing medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Alzheon has offered to sell 2.5 million shares of its common stock in the offering, and the underwriters have an option for 30 days to purchase up to 375 thousand additiona
10/20/18 - Board of directors meeting of Macter International Limited
Macter International Limited informed Pakistan Stock Exchange that board of directors meeting of the company will be held on October 27, 2018 at Karachi. Macter International Limited is amongst the leading Pharmaceutical companies in Pakistan. Macter is a public limited company and has a successful 30 years track record in the manufacturing of phar
10/20/18 - Cantargia Presented Positive Phase I Clinical Data with Lead Candidate CAN04 at ESMO
Cantargia AB today presented interim results from its clinical Phase I/II trial CANFOUR of lead candidate CAN04 in a poster presentation at the ESMO Congress 2018 in Munich, Germany. The poster presentation with the title A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein, in patients
10/20/18 - Castle Creek Pharma Announces $71.8 Million in New Investment to Expand Research for Rare Dermatologic Conditions [Tehran Times (Iran)]
Castle Creek plans to use this additional funding to support the late-stage development of an investigational drug, diacerein ointment. We are focused on developing CCP-020 as an important treatment for EBS and look forward to targeting the new investment from Fidelity and Valor towards the late-stage development of this investigational drug, said.
10/20/18 - Clearside Biomedical Appoints Veteran Supply Chain Executive, Thomas Crawford, as Vice President, Supply Chain [Palestine News Agency (WAFA)]
-Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas Crawford, CSCP, as Vice President, Supply Chain. Crawfords earlier experience includes supply chain, manufacturing and trade relations management
10/20/18 - First Presentation of Early Data for Merck's Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING agonist, as monotherapy and in combination with KEYTRUDA , Merck s anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas. MK-1454 is one
10/20/18 - Generic Drugs Market with Clinical Analysis Is Expected to Grow at a CAGR of 10.0% from 2018 to 2025
Harrisburg, NC 10/19/2018 Global Generic Drugs Market Insights, Forecast To 2025; presents an in-depth assessment of the Generic Drugs including new developments, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, player profiles
10/20/18 - INNATE PHARMA : Phase II results from monalizumab/cetuximab in head and neck cancer at ESMO
Innate Pharma SA, today announced updated data from the Phase II trial evaluating the safety and efficacy of the combination of monalizumab and cetuximab in previously treated patients with recurrent and/or metastatic squamous cell carcinoma of the head& neck. The data will be discussed today at the ESMO 2018 Congress in Munich, Germany, by Profess
10/20/18 - Janssen Announces Three-Year TREMFYA(R) (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients With Moderate to Severe Plaque Psoriasis
Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:. The Janssen Pharmaceutical Companies of Johnson& Johnson announced today new long-term data from the open-label period of the VOYAGE 1 clinical trial demonstrating that stably maintained rates of skin clearance with TREMFYA (R) treatment achie
10/20/18 - Maryland; Baltimore; Baltimore County; Frosh appeals ruling against 'price-gouging' law; More KKK fliers turn up around neighborhood ; Goucher College president to step down in 2019
Maryland Attorney General Brian Frosh appealed Friday to the U.S. Supreme Court an earlier decision by a federal court that struck down a Maryland law to curb unreasonable price increases for generic drugs. In response to an industry challenge, the 4th U.S. Circuit Court of Appeals decided in April that the first-of-its-kind legislation violates th
10/20/18 - Merrimack Pharmaceuticals shares tumble on termination of Phase 2 trial for lung cancer treatment [Sudan Tribune]
Shares of Merrimack Pharmaceuticals Inc plunged in Fridays pre-market session after the clinical-stage oncology company announced it terminated a Phase 2 trial for its treatment of non-small cell lung cancer due to its failure to improve patients chances for survival. In the wake of the move, the Cambridge, Massachusetts- based company is starting
10/20/18 - New Drug Could Sustain Oxygen-Starved Hearts
The University of California issued the following news release:. "Any tissue with compromised blood flow, whether due to trauma, stroke, or heart disease, could potentially be targeted by a treatment like this," said Emin Maltepe, MD, PhD, associate professor of pediatrics at UCSF and co-senior author of the paper. The new drug, called OMX-CV, was
10/20/18 - Novotech and CNS deal expands CRO services [Tehran Times (Iran)]
Novotech, the largest Asia-Pacific- based CRO, has acquired Australasian specialist CRO Clinical Network Services, as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials. Early phase CNS clients, wishing to advance into later phase regio
10/20/18 - Okanagan clinical team to research Alzheimers Disease drug [Syrian Arab News Agency]
The Medical Arts Health Research Group will carry out a phase 3 study in the research process, which if successful would lead next to Health Canada and U.S. Food and Drug Administration approval, with further followup research efforts carried out for the medication after public certification on a wider basis. As doctors, nurses and caregivers, find
10/20/18 - OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced interim results from its ongoing Phase 1 b trial investigating navicixizumab, OncoMed s anti-DLL4/VEGF bispecific antibody, in combination with paclitaxel in patients with...
10/20/18 - Paragon Biosciences Announces $71.8 Million in New Investment for Portfolio Company Castle Creek Pharma [Tehran Times (Iran)]
-Paragon Biosciences today announced the completion of a new capital investment of $71.8 million for Castle Creek Pharma, a Paragon portfolio company. Paragon organized the $71.8 million investment in Castle Creek from respected firms, Fidelity Management& Research Company and Valor Equity Partners, for late-stage development of treatments for rare
10/20/18 - PDA Adopts Projects to Assist Pharma Manufacturers Data Governance and Predictive Maintenance Projects Formed After Consultation With PDA Manufacturing Science and Operations Program
The Parenteral Drug Association issued the following news release:. The Parenteral Drug Association is pleased to announce the formation of a PDA technical report team and a task force to advance projects to assist pharmaceutical manufacturers in key areas. Both projects are part of the overarching PDA/MSOP Manufacturing Intelligence Task Force,...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415